BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30694451)

  • 1. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan.
    Kawashima N; Iida M; Suzuki R; Fukuda T; Atsuta Y; Hashii Y; Inoue M; Kobayashi M; Yabe H; Okada K; Adachi S; Yuza Y; Kawa K; Kato K
    Int J Hematol; 2019 Apr; 109(4):491-498. PubMed ID: 30694451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
    Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.
    Iida M; Fukuda T; Uchida N; Murata M; Aotsuka N; Minagawa K; Oohashi K; Fukushima K; Kondo T; Eto T; Miyamoto T; Morishima Y; Nagamura T; Atsuta Y; Suzuki R
    Clin Transplant; 2014 Sep; 28(9):980-9. PubMed ID: 24943923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
    Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.
    Nakane T; Nakamae H; Yamaguchi T; Kurosawa S; Okamura A; Hidaka M; Fuji S; Kohno A; Saito T; Aoyama Y; Hatanaka K; Katayama Y; Yakushijin K; Matsui T; Yamamori M; Takami A; Hino M; Fukuda T
    Int J Hematol; 2017 Apr; 105(4):485-496. PubMed ID: 27943166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
    Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients.
    Kurata K; Yakushijin K; Okamura A; Yamamori M; Ichikawa H; Sakai R; Mizutani Y; Kakiuchi S; Miyata Y; Kitao A; Kawamoto S; Matsuoka H; Murayama T; Minami H
    Cancer Chemother Pharmacol; 2018 May; 81(5):839-846. PubMed ID: 29511796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
    Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Inui Y; Yakushijin K; Okamura A; Tanaka Y; Shinzato I; Nomura T; Ichikawa H; Mizutani Y; Kitao A; Kurata K; Kakiuchi S; Miyata Y; Sanada Y; Kitagawa K; Uryu K; Kawamoto S; Yamamoto K; Matsuoka H; Murayama T; Ito M; Minami H
    Transpl Infect Dis; 2019 Feb; 21(1):e13024. PubMed ID: 30414316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.
    Kasper C; Sayer HG; Mügge LO; Schilling K; Scholl S; Issa MC; Höffken K
    Bone Marrow Transplant; 2004 Jan; 33(1):65-9. PubMed ID: 14704658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.
    Iida M; Fukuda T; Ikegame K; Yoshihara S; Ogawa H; Taniguchi S; Takami A; Abe Y; Hino M; Etou T; Ueda Y; Yujiri T; Matsui T; Okamura A; Tanaka J; Atsuta Y; Kodera Y; Suzuki R
    Int J Hematol; 2011 Apr; 93(4):523-531. PubMed ID: 21465117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.
    Harnicar S; Ponce DM; Hilden P; Zheng J; Devlin SM; Lubin M; Pozotrigo M; Mathew S; Adel N; Kernan NA; O'Reilly R; Prockop S; Scaradavou A; Hanash A; Jenq R; van den Brink M; Giralt S; Perales MA; Young JW; Barker JN
    Biol Blood Marrow Transplant; 2015 May; 21(5):920-5. PubMed ID: 25687796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
    Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
    Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation.
    Johnston L; Florek M; Armstrong R; McCune JS; Arai S; Brown J; Laport G; Lowsky R; Miklos D; Shizuru J; Sheehan K; Lavori P; Negrin R
    Bone Marrow Transplant; 2012 Apr; 47(4):581-8. PubMed ID: 21552302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.
    Bejanyan N; Rogosheske J; DeFor T; Lazaryan A; Esbaum K; Holtan S; Arora M; MacMillan ML; Weisdorf D; Jacobson P; Wagner J; Brunstein CG
    Biol Blood Marrow Transplant; 2015 May; 21(5):926-33. PubMed ID: 25655791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
    Zhu X; Lai X; Luo Y; Shi J; Tan Y; Zheng W; He J; Xie W; Li L; Zhang J; Ye X; Lin M; Cai Z; Huang H
    Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.